Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

JACC: Heart Failure

Volumn 4, Issue 6, 2016, Pages 441-449

  Hoeper, Marius M ^a   Meyer, Katrin ^a   Rademacher, Jessica ^a   Fuge, Jan ^a   Welte, Tobias ^a   Olsson, Karen M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diffusion capacity; Heart failure; Hypertension; Pulmonary; Smoking; Survival

Indexed keywords

CARBON MONOXIDE;

AGED; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORRELATIONAL STUDY; FEMALE; HEART CATHETERIZATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; SURVIVAL RATE; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; CARBON MONOXIDE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DIFFUSING CAPACITY; RETROSPECTIVE STUDIES; STROKE VOLUME;

EID: 84971384492     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.12.016     Document Type: Article

References (41)

1. Klapholz M., Maurer M., Lowe A.M., et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004, 43:1432-1438. for the New York Heart Failure Consortium.
2. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., Redfield M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009, 53:1119-1126.
3. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
4. Borlaug B.A., Lam C.S., Roger V.L., Rodeheffer R.J., Redfield M.M. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009, 54:410-418.
5. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
6. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
7. Bursi F., McNallan S.M., Redfield M.M., et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012, 59:222-231.
8. Kjaergaard J., Akkan D., Iversen K.K., et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007, 99:1146-1150.
9. Vachiery J.L., Adir Y., Barbera J.A., et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013, 62(Suppl 25):D100-D108.
10. Fang J.C., DeMarco T., Givertz M.M., et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult-a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2012, 31:913-933.
11. Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015, 46:903-975.
12. Souza R., Fernandes C.J., Hoeper M.M. Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension. Eur Respir J 2014, 43:963-965.
13. Steenhuis L.H., Groen H.J., Koeter G.H., van der Mark T.W. Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J 2000, 16:276-281.
14. Burke C.M., Glanville A.R., Morris A.J., et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987, 42:131-135.
15. Trip P., Nossent E.J., de Man F.S., et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J 2013, 42:1575-1585.
16. Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:189-194.
17. Cottin V., Le Pavec J., Prevot G., et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010, 35:105-111. for the GERM"O"P Investigators.
18. Cottin V., Nunes H., Brillet P.Y., et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005, 26:586-593. for the GERM"O"P Investigators.
19. Agarwal R., Shah S.J., Foreman A.J., et al. Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. J Heart Lung Transplant 2012, 31:467-477.
20. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993, 16:5-40.
21. Macintyre N., Crapo R.O., Viegi G., et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720-735.
22. Eaton T., Rudkin S., Garrett J.E. The clinical utility of arterialized earlobe capillary blood in the assessment of patients for long-term oxygen therapy. Respir Med 2001, 95:655-660.
23. Hoeper M.M., Bogaard H.J., Condliffe R., et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013, 62(Suppl 25):D42-D50.
24. Borland C., Cox Y., Higenbottam T. Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension. Thorax 1996, 51:855-856.
25. Puri S., Baker B.L., Dutka D.P., Oakley C.M., Hughes J.M., Cleland J.G. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure: its pathophysiological relevance and relationship to exercise performance. Circulation 1995, 91:2769-2774.
26. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008, 14:695-702.
27. Agostoni P., Bussotti M., Cattadori G., et al. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J 2006, 27:2538-2543.
28. Melenovsky V., Andersen M.J., Andress K., Reddy Y.N., Borlaug B.A. Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications. Eur J Heart Fail 2015, 17:1161-1171.
29. Schiess R., Senn O., Fischler M., et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010, 138:1086-1092.
30. Tuder R.M., Archer S.L., Dorfmuller P., et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013, 62(Suppl 25):D4-D12.
31. Montani D., Price L.C., Dorfmuller P., et al. Pulmonary veno-occlusive disease. Eur Respir J 2009, 33:189-200.
32. Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., Kimmel S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350.
33. Overbeek M.J., Vonk M.C., Boonstra A., et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009, 34:371-379.
34. Langleben D., Heneghan J.M., Batten A.P., et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med 1988, 109:106-109.
35. Dorfmuller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.
36. Wang K.Y., Tanimoto A., Inenaga T., et al. Pulmonary capillary hemangiomatosis in chronic cardiac failure due to aortic stenosis. J UOEH 2009, 31:339-344.
37. Jing X., Yokoi T., Nakamura Y., et al. Pulmonary capillary hemangiomatosis: a unique feature of congestive vasculopathy associated with hypertrophic cardiomyopathy. Arch Pathol Lab Med 1998, 122:94-96.
38. Schraufnagel D.E., Sekosan M., McGee T., Thakkar M.B. Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. Eur Respir J 1996, 9:346-350.
39. Ferrer E., Peinado V.I., Castaneda J., et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J 2011, 38:617-627.
40. Seimetz M., Parajuli N., Pichl A., et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011, 147:293-305.
41. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.